PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Amoxi Clavulanate

Drugs in development · updated 30 October 2026

Amoxi Clavulanate: clinical trials and development status

Other names and codes: Amoxicillin clavulanic acid, Augmentin

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Amoxi Clavulanate is in 5 active clinical trials (recruiting or ongoing, phases I–III) for 8 diseases. The most advanced phase is III.

5Active trials
IIIMost advanced phase
8Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Amoxi Clavulanate and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Chronic coughIII1NCT07582549
InfectionII–III1NCT07202052
LeukemiaII–III1NCT07202052
LymphomaII–III1NCT07202052
NeoplasmII–III1NCT07202052
Non-Hodgkin lymphomaII–III1NCT07202052
Plasma cell neoplasmII–III1NCT07202052
Erectile dysfunctionEarly I1NCT05100654

Everything on Amoxi Clavulanate

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch